Atezolizumab approved for advanced alveolar soft part sarcoma

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS.

Atezolizumab approved for advanced alveolar soft part sarcoma - NCI

A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft ...

FDA grants approval to atezolizumab for alveolar soft part sarcoma

On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of ...

Atezolizumab for Advanced Alveolar Soft Part Sarcoma - PubMed

Conclusions: Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS. (Funded by ...

Atezolizumab Shrinks Alveolar Soft Part Sarcomas - NCI

Treatment with atezolizumab (Tecentriq) shrank tumors in nearly 40% of people with alveolar soft part sarcoma, according to new clinical ...

Atezolizumab as the First Systemic Therapy Approved for Alveolar ...

Atezolizumab was granted approval by the FDA specifically for ASPS based on a phase II clinical trial in adult and pediatric patients.

A Robust, Durable Activity of Atezolizumab Observed in a Diverse

1 occurred in approximately one third (37%) of the patients with alveolar soft part sarcoma, many of whom had disease progression during ...

Atezolizumab induces durable responses in advanced alveolar soft ...

Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data ...

Phase II study of atezolizumab in advanced alveolar soft part ...

Background: ASPS constitutes < 1% of soft tissue sarcomas and frequently presents in adolescents and young adults. There are no approved ...

FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma - OncLive

The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part ...

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Atezolizumab was effective at inducing sustained responses in approximately one third of patients with advanced ASPS.

Exploring Atezolizumab With or Without Bevacizumab in Alveolar ...

“The recent FDA approval for atezolizumab in the metastatic setting is the first checkpoint inhibitor to be approved for ASPS. Actually, it's ...

Phase II study of atezolizumab in advanced alveolar soft part ...

11519 Background: ASPS constitutes < 1% of soft tissue sarcomas and frequently presents in adolescents and young adults. There are no approved therapies for ...

Atezolizumab Approved for Alveolar Soft Part Sarcoma

The FDA has granted approval to atezolizumab (Tecentriq®, Genentech, Inc.) for treatment of unresectable or metastatic alveolar soft part sarcoma (ASPS) in ...

First treatment approval for advanced ASPS

A Phase II trial has led to the FDA approval of atezolizumab for individuals over two years old with advanced alveolar soft part sarcoma.

FDA D.I.S.C.O. Burst: Tecentriq and Krazati

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati ( ...

Atezolizumab Yields Durable Responses in Alveolar Soft Part ...

Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.

FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma

The FDA has approved atezolizumab (Tecentriq) to treat adults and children aged 2 years or older with unresectable or metastatic alveolar ...

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

This study supports the use of atezolizumab as a safe and effective treatment in patients with advanced alveolar soft part sarcoma. Further ...

Atezolizumab as the First Systemic Therapy Approved for Alveolar ...

Atezolizumab was approved in the treatment of ASPS based on the results of a phase 2, multicenter, single-arm, open-label clinical trial in adult and pediatric ...